^
    Back
    Association details:
    Biomarker:BCR-ABL1 fusion
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:S63845 (MCL1 inhibitor) +
    S55746 (Bcl2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2018
    Title:

    Identification of Potent BH3-Mimetic Combinations Targeting Pro-Survival Pathways in Human B-Cell Acute Lymphoblastic Leukemia

    Published date:
    11/01/2018
    Excerpt:
    Preliminary data using patient-derived xenografts in NSG mice revealed in vivo efficacy of combined S55746 and S63845 therapy against 3 adult B-ALL cases (1 Ph+ and 2 Ph-).
    DOI:
    doi.org/10.1182/blood-2018-99-114051